-
Dogwood Therapeutics NasdaqCM:DWTX Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include Halneuron, which is in late-stage clinical development for the treatment of chemotherapy-induced neuropathic pain; IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia; and IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is headquartered in Alpharetta, Georgia.
Location: 44 Milton Avenue, Alpharetta, GA, 30009, United States | Website: https://www.dwtx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
69.93M
Cash
14.85M
Avg Qtr Burn
N/A
Short % of Float
13.46%
Insider Ownership
14.98%
Institutional Own.
7.95%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IMC-1 (famciclovir + celecoxib) Details Fibromyalgia | Phase 3 Initiation | |
Halneuron Details Chemotherapy-induced neuropathic pain | Phase 2b Data readout | |
IMC-2 (valacyclovir and celecoxib) Details Long COVID-19 | Phase 2a Update |